Program
LPM3770164
A development code. Also written as “LPM3770164 sustained release tablet”, “LY03015 (LPM3770164 extended-release tablets)” and “[14C] LPM3770164”.
Its studies are mostly in Huntington Disease · Tardive Dyskinesia, led by Luye Pharma Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Luye Pharma Group | 62 open or running | phase 2since Dec 9, 2024 | Jan 9, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2022First study: phase 1 study in Huntington DiseaseFirst studyNCT05238701 · 104 enrolled · China
- Dec 19, 2023Phase 1 study in Tardive DyskinesiaNCT06216054 · 40 enrolled · China
- Jun 20, 2024Phase 1 study in Huntington DiseaseNCT06474650 · 16 enrolled · China
- Dec 9, 2024Phase 2 study in Tardive DyskinesiaNCT06731868 · 120 planned · China
- Apr 1, 20262 phase 1 studiesNCT07516899, NCT07671833
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07671833Healthy Participants · United States | 1 | Completed | May 8, 2026 | 24 |
| NCT07516899Huntington Disease · China | 1 | Not yet recruiting | Jun 30, 2026 | 8 |
| NCT06731868Tardive Dyskinesia · China | 2 | Recruiting | Oct 31, 2025 | 120 |
| NCT06474650Huntington Disease · China | 1 | Completed | Sep 25, 2024 | 16 |
| NCT06216054Tardive Dyskinesia · China | 1 | Completed | Jul 29, 2024 | 40 |
| NCT05238701Huntington Disease · China | 1 | Completed | Nov 4, 2023 | 104 |
How it is read
Names in the registry
- “LPM3770164 sustained release tablet”, 3 entries
- “LY03015 (LPM3770164 extended-release tablets)”, 1 entry
- “[14C] LPM3770164”, 1 entry
- “LPM3770164 sustained release tablet 5 mg”, 1 entry
- “LPM3770164 sustained release tablet 10 mg”, 1 entry
Codes read as this program: LY03015, LPM3770164.
Conditions, from the studies’ own filings
- Huntington Disease, 3 studies
- Tardive Dyskinesia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.